3D Medicines Inc. (1244.HK)

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China. It offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. The company's products in development pipeline include 3D189 for multi-indication tumor and is in phase III clinical trial; 3D229 (GAS6/AXL) for non-small cell lung cancer, ovarian cancer, and kidney cancer and is in phase III clinical trial; 3D1001 for the treatment of postoperative dental pain and tumor pain which is in phase II trial; 3D1002 for oncology pain and is in phase II trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumor, and 3D057 for multiple indications tumors. 3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.